Stock Events

Stock Events

CytomX Therapeutics 

$3.68
61
-$0.04-1.08% Thursday 20:00
+$0.04+0.98%Thursday 23:51After hours

Statistics

Day High
3.68
Day Low
3.67
52W High
8.21
52W Low
1.9
Volume
63,272
Avg. Volume
-
Mkt Cap
801.87M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.2
-0.04
0.11
0.27
Expected EPS
-0.071913
Actual EPS
N/A

Financials

-22.79%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
76.2MRevenue
-17.37MNet Income

Analyst Ratings

13.14Average Price Target
The highest estimate is 16.00.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CTMX. It's not an investment recommendation.
NVIDIA
11
NVDA
Amazon
10
AMZN
Coca-Cola
10
KO
AMD
10
AMD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap366B
Merck & Co. competes in the oncology space with its strong portfolio of cancer treatments, potentially overlapping with CytomX's cancer therapies.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb offers a range of oncology products that could be in direct competition with CytomX's therapeutic candidates.
AMGEN
AMGN
Mkt Cap233.78B
Amgen has a diverse oncology portfolio, including innovative biologics that could compete with CytomX's antibody-based therapies.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG, through its Genentech subsidiary, develops targeted cancer therapies, potentially competing with CytomX's approach to cancer treatment.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a broad oncology division, with treatments that could directly compete with CytomX's cancer therapies.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, known for its oncology and immuno-oncology portfolio, could pose competition to CytomX's therapeutic approaches.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca has a strong focus on oncology, with several treatments that could compete with CytomX's pipeline.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals, with its focus on innovative biologics for cancer, could be a competitor to CytomX's technology.
Novartis
NVS
Mkt Cap292.35B
Novartis AG has a comprehensive oncology portfolio, including targeted therapies that could compete with CytomX's cancer treatments.

About

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Show more...
CEO
Sean A. McCarthy
Employees
69
Country
United States
ISIN
US23284F1057
WKN
000A14158

Listings

STU
DE
6C1.STU
XNAS
US
CTMX
F
DE
6C1.F
BOATS
BOATS
CTMX.BOATS

0 Comments

Share your thoughts

FAQ

What is CytomX Therapeutics stock price today?▼
The current price of CTMX is $3.68 USD — it has decreased by -1.08% in the past 24 hours. Watch CytomX Therapeutics stock price performance more closely on the chart.
What is CytomX Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange CytomX Therapeutics stocks are traded under the ticker CTMX.
Is CytomX Therapeutics stock price growing?▼
CTMX stock has risen by +14.64% compared to the previous week, the month change is a +10.84% rise, over the last year CytomX Therapeutics has showed a +75.24% increase.
What is CytomX Therapeutics market cap?▼
Today CytomX Therapeutics has the market capitalization of 801.87M
When is the next CytomX Therapeutics earnings date?▼
CytomX Therapeutics is going to release the next earnings report on November 10, 2026.
What were CytomX Therapeutics earnings last quarter?▼
CTMX earnings for the last quarter are -0.09 USD per share, whereas the estimation was -0.08 USD resulting in a -16.76% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is CytomX Therapeutics revenue for the last year?▼
CytomX Therapeutics revenue for the last year amounts to 76.2M USD.
What is CytomX Therapeutics net income for the last year?▼
CTMX net income for the last year is -17.37M USD.
How many employees does CytomX Therapeutics have?▼
As of September 04, 2026, the company has 69 employees.
In which sector is CytomX Therapeutics located?▼
CytomX Therapeutics operates in the Health & Wellness sector.
When did CytomX Therapeutics complete a stock split?▼
CytomX Therapeutics has not had any recent stock splits.
Where is CytomX Therapeutics headquartered?▼
CytomX Therapeutics is headquartered in SOUTH SAN FRANCISCO, United States.